Sandra Garcet Selected Research

fezakinumab

1/2019	Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.
1/2018	Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sandra Garcet Research Topics

Disease

19	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2022 - 01/2017
10	Inflammation (Inflammations) 01/2022 - 01/2017
7	Atopic Dermatitis (Atopic Eczema) 01/2022 - 01/2016
5	Hyperplasia 01/2022 - 01/2017
5	Hidradenitis Suppurativa 01/2022 - 11/2020
2	Alopecia (Baldness) 10/2022 - 01/2022
2	Alopecia Areata 10/2022 - 01/2022
2	Melanoma (Melanoma, Malignant) 01/2019 - 10/2016
1	Skin Diseases (Skin Disease) 01/2022
1	Erythema 01/2021
1	Obesity 01/2020
1	Parakeratosis 01/2020
1	Necrosis 01/2020
1	Dermatitis 10/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2018
1	Keloid 01/2017
1	Neoplasm Metastasis (Metastasis) 10/2016

Drug/Important Bio-Agent (IBA)

8	CytokinesIBA 11/2021 - 01/2017
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2017
6	Ustekinumab (CNTO 1275)FDA Link 01/2022 - 01/2017
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2017
6	Interleukin-17 (Interleukin 17)IBA 01/2021 - 11/2017
3	Keratin-16 (Keratin 16)IBA 01/2022 - 01/2017
3	brodalumabIBA 01/2022 - 01/2020
3	Interleukin-22 (IL-22)IBA 01/2020 - 01/2018
2	dupilumabIBA 10/2022 - 01/2022
2	SaltsIBA 10/2022 - 01/2022
2	secukinumabIBA 05/2022 - 01/2021
2	ProteomeIBA 01/2022 - 01/2021
2	Blood Proteins (Serum Proteins)IBA 01/2022 - 01/2018
2	Lipocalin-2IBA 01/2022 - 01/2021
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 10/2019
2	Monoclonal AntibodiesIBA 01/2022 - 01/2018
2	Messenger RNA (mRNA)IBA 01/2021 - 01/2017
2	loricrinIBA 01/2021 - 01/2019
2	SteroidsIBA 01/2021 - 01/2016
2	Filaggrin ProteinsIBA 01/2021 - 01/2019
2	fezakinumabIBA 01/2019 - 01/2018
2	Etanercept (Enbrel)FDA Link 01/2019 - 01/2018
2	Interleukin-12 (IL 12)IBA 01/2019 - 01/2017
1	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2022
1	InterleukinsIBA 01/2022
1	spesolimabIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 11/2021
1	Abatacept (Orencia)FDA Link 11/2021
1	S100 Calcium Binding Protein A7IBA 01/2021
1	Cathepsin DIBA 01/2021
1	MART-1 AntigenIBA 01/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020
1	Pharmaceutical PreparationsIBA 01/2020
1	Interleukin-17 ReceptorsIBA 01/2020
1	InterferonsIBA 01/2020
1	PF-06700841IBA 01/2020
1	Janus Kinase 1IBA 01/2020
1	AnisomycinIBA 10/2019
1	p38 Mitogen-Activated Protein KinasesIBA 10/2019
1	doramapimodIBA 10/2019
1	Imiquimod (Aldara)FDA LinkGeneric 10/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	risankizumabIBA 01/2019
1	Interleukin-23 (Interleukin 23)IBA 01/2019
1	Interleukin-23 Subunit p19IBA 01/2019
1	apremilastIBA 01/2018
1	tofacitinibIBA 01/2018
1	ThrombospondinsIBA 11/2017
1	AutoantigensIBA 11/2017
1	AntigensIBA 11/2017
1	LipidsIBA 11/2017
1	DisintegrinsIBA 11/2017
1	Metalloproteases (Metalloproteinases)IBA 11/2017
1	CathelicidinsIBA 11/2017
1	Phospholipases A2 (Phospholipase A2)IBA 11/2017
1	Fibrillin-2IBA 01/2017
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2017
1	OsteopontinIBA 01/2017
1	osteoblast cadherinIBA 01/2017
1	Transcription Factors (Transcription Factor)IBA 01/2017
1	Collagen Type XIBA 01/2017
1	diphenylcyclopropenoneIBA 10/2016

Therapy/Procedure

2	Aftercare (After-Treatment) 10/2022 - 01/2022
1	Retreatment 01/2020
1	Therapeutics 11/2017